As of Thursday close, Charles River Laboratories International Inc.’s (NYSE:CRL) stock was down -$10.48, moving down -5.02 percent to $198.15. The average number of shares traded per day over the past five days has been 809,000 shares. 2 times new highs have been achieved over the past 5 days, with a -$9.61 fall in that time frame. In the last twenty days, the average volume was 499,400, while in the previous 50 days, it was 487,840.
Since last month, CRL stock retreated -1.03%. Shares of the company fell to $193.58 on 09/21/23, the lowest level in the past month. A 52-week high of $262.00 was reached on 02/08/23 after having rallying from a 52-week low of $181.22. Since the beginning of this year, CRL’s stock price has dropped by -9.06% or -$19.75, and marked a new high 8 times. However, the stock has declined by -24.37% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
CRL stock investors should be aware that Charles River Laboratories International Inc. (CRL) stock had its last reported insider trading activity 29 days ago on Aug 24. WALLMAN RICHARD F, the Director of the company, purchased of 1,000 shares for $198.79 on Aug 24. It resulted in a $198,786 investment by the insider. Barbo William D sold 5,763 shares at an average price of $217.24 on Aug 10. The insider now owns 3,592 shares following the transaction. On Aug 10, CSVP&Chief Accounting Officer Knell Michael Gunnar sold 1,471 shares at $216.54 apiece. The transaction was valued at $318,530.
Valuation Metrics
Right now, Charles River Laboratories International Inc. (CRL) has a P/E ratio of about 21.03. The stock’s beta is 1.33. Besides these, the trailing price-to-sales (P/S) ratio of 2.43, the price-to-book (PB) ratio of 3.12, and the price-to-cash flow ratio of 35.10 may also be considered.
Financial Health
In the three months ended June 29, Charles River Laboratories International Inc.’s quick ratio stood at 1.20, while its current ratio was 1.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.82, and the total debt-to-equity ratio was 0.82. On the profitability front, the trailing twelve-month gross margin is 37.00% percent. In the year ended June 29, EBITDA margin amounted to 24.06%, whereas operating margins totaled 18.50%. Based on annual data, CRL earned $1.46 billion in gross profit and brought in $3.98 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 9.50%. Return on equity (ROE) for the past 12 months was 16.20%.
In Charles River Laboratories International Inc.’s quarter-end financial report for June 29, it reported total debt of $2.68 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CRL’s revenue rose 8.19% to $1.03 billion during the quarter, while net income inched up to $1.06 billion. While analysts expected Charles River Laboratories International Inc. to report $2.64 quarterly earnings, the actual figure was $2.69 per share, beating the consensus estimate by 1.90%. During the quarter, the company generated $242.62 million in EBITDA. The liabilities of Charles River Laboratories International Inc. were 4.51 billion at the end of its most recent quarter ended June 29, and its total debt was $3.08 billion. The value of shareholders’ equity is $51.27 million.
Technical Picture
This quick technical analysis looks at Charles River Laboratories International Inc.’s (CRL) price momentum. With a historical volatility rate of 35.63%, the RSI 9-day stood at 37.51% on 21 September.
With respect to its five-day moving average, the current Charles River Laboratories International Inc. price is down by -4.63% percent or -$9.61. At present, CRL shares trade -1.91% below its 20-day simple moving average and +4.22% percent above its 100-day simple moving average. However, the stock is currently trading approximately -6.09% below its SMA50 and -11.01% below its SMA200.
Stochastic coefficient K was 58.60% and Stochastic coefficient D was 72.77%, while ATR was 6.33. Given the Stochastic reading of 23.48% for the 14-day period, the RSI (14) reading has been calculated as 41.77%. As of today, the MACD Oscillator reading stands at 0.45, while the 14-day reading stands at 0.50.
Analyst Ratings
TD Cowen launched its rating on Charles River Laboratories International Inc. (NYSE: CRL) to a Market perform in a note to investors on September 13, 2023. Charles River Laboratories International Inc. (CRL) has been rated Overweight by analysts. According to 0 brokerage firms, CRL is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate Charles River Laboratories International Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $250.00, the current consensus forecast for the stock is $207.00 – $280.00. Based on these forecasts, analysts predict Charles River Laboratories International Inc. (CRL) will achieve an average price target of $242.31.
